Morgan Stanley Maintains Equal-Weight on Mirati Therapeutics, Lowers Price Target to $37
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Michael Ulz has maintained an Equal-Weight rating on Mirati Therapeutics (NASDAQ:MRTX) and lowered the price target from $42 to $37.
August 09, 2023 | 1:45 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Morgan Stanley has maintained an Equal-Weight rating on Mirati Therapeutics and lowered the price target from $42 to $37.
The lowering of the price target by Morgan Stanley indicates a potential decrease in the stock's value. This could lead to a negative short-term impact on the stock's price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100